Peptides for libido and sexual health
Desire and arousal start in the brain, not just the body — which is why research on peptides for libido targets brain pathways. PT-141 (bremelanotide) works on melanocortin receptors; kisspeptin sits at the top of the hormone axis that runs reproduction.
These articles explain that biology plainly and cover what studies show for both men and women. Everything is prescription-only: a licensed provider reviews each request, and not everyone qualifies. Timing, dosing, and side effects are covered in the individual articles below.
29 articles on this topic
-
Semaglutide and Testosterone: What Studies Show
Low testosterone may rise as men with obesity lose weight on semaglutide. Small studies support that link, but a direct hormone effect remains unproven.
-
10 Questions to Ask Before PT-141
A PT-141 visit starts with fit and safety. These ten questions clarify the evidence, medical history, side effects, and follow-up plan.
-
Vyleesi Prescribing Information, in Plain English
Vyleesi's label covers one specific form of low desire, a fixed injection dose, and safety limits. Here are its sections in everyday language.
-
Who Discovered PT-141? It Began as a Tanning Drug
PT-141 began as an accident: a University of Arizona tanning peptide caused unexpected erections in its first volunteers. Here is how that clue became bremelanotide, and what happened to its gray-market sibling.
-
PT-141 News Update: September 2026
The Vyleesi label didn't change this quarter. What did: FDA warning letters that named PT-141 sold online, a lab study on how the peptide breaks down, and a warning about its tanning-drug cousin.
-
PT-141 Clinical Trials: What RECONNECT Found
The pivotal studies found modest improvements in desire and distress in a specific group of premenopausal women. They also found a high nausea rate, a sizable placebo response, and clear limits on what the results can tell us about men or compounded PT-141.
-
Who Discovered Kisspeptin? The People Behind It
Danny Welch's cancer research started the story in 1996. Other teams found the peptide, connected it to puberty, and brought it into human studies.
-
Kisspeptin Dose: What Human Studies Actually Used
There is no standard kisspeptin dose to copy from a study. Human trials used different peptide forms, routes, and schedules, so a prescription has to be set for the person and the clinical goal.
-
Kisspeptin Supplement: A Capsule Isn't the Peptide
A capsule sold as a kisspeptin supplement does not deliver the peptide used in the hormone and fertility studies people usually quote. Those studies used a vein or an injection under the skin, not an ordinary pill.
-
PT-141 Half-Life Is About 2.7 Hours
The number is short, but it is not a stopwatch for how long someone feels an effect. Here is what the label's timing, clearance range, and safety limits actually mean.
-
PT-141 10mg Vial: What That Number Means
Ten milligrams describes what is in the whole vial. It does not tell you what to draw up, how many uses you have, or how a nasal product compares; those answers come from the prescription and pharmacy label.
-
Kisspeptin vs PT-141: They Work Differently
Kisspeptin and PT-141 both enter libido conversations, but they act on different systems and do not share the same evidence. PT-141 has larger trials and an approved branded product; kisspeptin's human data are smaller and earlier.
-
How to Use PT-141: It's As-Needed, Not Daily
PT-141 is taken before anticipated activity rather than on a daily schedule. Here is what the approved label sets out, what a compounded vial changes, and what the prescriber decides.
-
Kisspeptin-54 vs Kisspeptin-10: Why Length Matters
Kisspeptin-54 is the whole peptide; kisspeptin-10 is its last ten amino acids. The long one lasts about seven times longer in the blood, and that one fact explains which studies used which.
-
Kisspeptin for Women: What the Research Shows
Kisspeptin has been given to women in a handful of small hospital trials — to mature eggs during IVF, to restart stalled hormone signalling, and once to watch the brain respond to sexual cues. Here is what those studies found, and what they did not.
-
Kisspeptin and Testosterone: Pattern Beats Amount
A study published on August 3, 2026 gave 15 healthy men kisspeptin-10 three different ways. Five days of it around the clock and the pituitary stopped answering; eight hours on and sixteen off, and it kept answering for twelve days.
-
Kisspeptin Benefits: What Human Studies Found
In people, kisspeptin has done two things reliably: switched on the reproductive hormone system, and changed how the brain handles sexual cues. Nearly all of it was measured over hours, in a hospital.
-
Kisspeptin for Men: What the Studies Really Show
Kisspeptin may affect reproductive hormones and sexual response in men. The evidence is promising but small, and it does not establish a standard dose or long-term treatment plan.
-
Kisspeptin Side Effects: What Human Trials Found
Short human trials suggest few systemic effects, while injection-site stinging can happen and repeated exposure can blunt the hormone response. The major unknown is long-term safety.
-
PT-141 Benefits: What the Human Trials Show
The strongest evidence is specific: studies found higher desire scores and less distress about low desire in premenopausal women with HSDD. Earlier, smaller trials in men measured erectile response, not broad sexual performance.
Page 1 of 2 · 29 articles